Lataa...
Anti-CD20 monoclonal antibodies: reviewing a revolution
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment...
Tallennettuna:
| Julkaisussa: | Hum Vaccin Immunother |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6343614/ https://ncbi.nlm.nih.gov/pubmed/30096012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1508624 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|